Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP)
A 21-Hydroxy-6,19-oxidoprogesterone derivative of Formula (1): where R is —C(O)—CH 2 CH 3 , —C(O)—(CH 2 ) 2 —COOH, —C(O)—(CH 2 ) 7 —CH═CH—(CH 2 ) 7 —COOH, or —C(O)—PO 3 Na 2 .
1 - 13 . (canceled)
14 . A 21-Hydroxy-6,19-oxidoprogesterone derivative of Formula (1):
wherein R is selected for the group consisting of —C(O)—CH 2 CH 3 , —C(O)—(CH 2 ) 2 —COOH, —C(O)—(CH 2 ) 7 —CH═CH—(CH 2 ) 7 —COOH, and —C(O)—PO 3 Na 2 .
15 . The 21-hydroxy-6,19-oxidoprogesterone derivative of claim 14 , wherein R is C(O)—(CH 2 ) 2 —COOH.
16 . A composition comprising the 21-hydroxy-6,19-oxidoprogesterone derivative of claim 14 and a pharmaceutically acceptable carrier.
17 . A method of preparing the composition of claim 16 for the treatment of at least one disorder associated with a glucocorticoid imbalance comprising incorporating and mixing the 21-hydroxy-6,19-oxidoprogesterone derivative into the carrier to form the composition.
18 . A method for treating a disease comprising a glucocorticoid imbalance comprising administering the 21-hydroxy-6,19-oxidoprogesterone derivative of claim 14 , in an amount sufficient to treat the disease, to a patient in need thereof.
19 . The method of claim 18 , wherein the glucocorticoid imbalance is an excess of glucocorticoids.
20 . The method of claim 18 , wherein the disease is selected from the group consisting of Cushing's syndrome, iatrogenic hypercoticolism, and depression.